Senior Research Scientist / Research Director, Molecular Virology Novira Therapeutics
You are an experienced hands-on virologist and you will build a research laboratory for the discovery and
characterization of antiviral and immunomodulatory agents. You will be responsible for the establishment
of cell based models and technologies for the study of virus replication and virus-host interactions
including HBV and HIV biology. Innovative assay development for the evaluation of new targets, drug
candidates and establishment of projects and collaborations in preclinical sciences, animal models,
translational and experimental medicine will also be part of your responsibilities. Publication of impactful
research results is expected.
Ph.D. and at least 3 years of experience as an independent scientist in virology, cell biology, immunology
or a related discipline with hands-on experience in HBV or HIV biology preferred. Track record of high
impact publications and knowledge of state-of-the-art virology and cell biology methods. Highly effective
in performing as well as directing scientists in the establishment of in vitro and in vivo methods and
models and in establishing methods with collaborators and CROs. Proven ability to balance multiple and
often competing priorities and timelines and to be productive in a fast-paced team environment. Track
record of initiating and maintaining productive scientific collaborations. Proven record of excellent written,
verbal and presentation skills. Experience in drug discovery or moving antiviral or immunomodulatory
agents from discovery to clinical stage will be positively considered.
Who We Are
Novira Therapeutics is a venture-backed biotechnology company focused on the development and
commercialization of a novel class of antiviral therapeutics. The two lead programs address chronic
Hepatitis B infection and HIV, diseases with enormous worldwide significance, unmet needs, and billion
dollar market potential.
Novira?s oral drugs target the capsid of the virus, and offer a promising treatment option both as
monotherapy and in combination with current standards of care. HBV afflicts over 350 million people
worldwide, with only a single oral class of drugs available. The company?s antivirals potentially address
limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available,
polymerase inhibitors, are rarely curative and often require lifelong treatment, as well as in chronic HIV
infection, a disease for which the continued ability of the virus to mutate inevitably leads to drug-resistant
viral strains. Each of these limitations to the standard of care can potentially be addressed by capsid
inhibitors which feature a new mechanism of action.
In August 2012 the company secured a $23 million Series A financing co-led by new investors 5AM
Ventures and Canaan Partners and joined by WuXi PharmaTech as well as existing investors BioAdvance,
Mid-Atlantic Angel Group, Robin Hood Ventures and Delaware Crossing Investment Group (DCIG). With
this recent financing the company has substantial resources to develop these first-in-class therapies that
offer the promise to substantially improve outcomes in HBV and HIV patients.
Located in the greater Philadelphia area, the company is managed by a team of world class scientific
experts who are making rapid progress with Novira?s lead programs. Given the growing interest of HBV
by numerous pharmaceutical companies and its prevalence in Asia, Novira Therapeutics has begun to
attract the attention of potential corporate partners. With the company on track to enter the clinic in the
beginning of 2014 and the potential for near-term partnering opportunities, the company well is poised to
emerge as a leader in the antivirals arena.
||Radnor, PA |